Compare AstraZeneca plc (AZN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? AstraZeneca plc trades at $158.65 (market cap $248.14B), while Vanguard Total Stock Market Index Fund ETF trades at $381.98. The key difference: AstraZeneca plc pays a 2.01% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | VTI | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $381.78 |
52-Week Low | $147.06 | $311.68 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
VTI trades at $381.95, up 0.08% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF offers broad diversification with over 3,500 holdings and a low 0.03% expense ratio, as noted by The Motley Fool on August 11, 2026. Recent institutional activity includes mixed buying and selling, with a dividend scheduled for June 30, 2026.
Outlook remains positive for long-term investors due to low costs and market-wide exposure, but risks include market volatility and concentration in large-cap tech. Analyst sentiment is generally favorable, emphasizing VTI's role in foundational portfolios, though current high RSI levels indicate potential near-term pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
